CLNNClene Inc.

Nasdaq clene.com


$ 0.34 $ -0.02 (-6.64 %)    

Thursday, 23-May-2024 12:05:31 EDT
QQQ $ 454.82 $ -5.67 (-1.23 %)
DIA $ 398.57 $ -5.43 (-1.37 %)
SPY $ 530.36 $ -5.46 (-1.02 %)
TLT $ 91.26 $ -0.71 (-0.77 %)
GLD $ 225.37 $ -2.93 (-1.34 %)
$ 0.3642
$ 0.36
$ 0.00 x 0
$ 0.00 x 0
$ 0.34 - $ 0.36
$ 0.25 - $ 1.09
226,851
na
46.78M
$ 0.28
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 03-13-2024 12-31-2023 10-K
3 11-07-2023 09-30-2023 10-Q
4 08-14-2023 06-30-2023 10-Q
5 05-12-2023 03-31-2023 10-Q
6 03-13-2023 12-31-2022 10-K
7 11-07-2022 09-30-2022 10-Q
8 08-15-2022 06-30-2022 10-Q
9 05-09-2022 03-31-2022 10-Q
10 03-11-2022 12-31-2021 10-K
11 11-08-2021 09-30-2021 10-Q
12 08-09-2021 06-30-2021 10-Q
13 05-10-2021 03-31-2021 10-Q
14 03-29-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 benchmark-reiterates-buy-on-clene-maintains-5-price-target

Benchmark analyst Bruce Jackson reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $5 price target.

 hc-wainwright--co-reiterates-buy-on-clene-maintains-7-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $7 price target.

 clene-q1-eps-009-misses-008-estimate-sales-7300k-miss-12000k-estimate

Clene (NASDAQ:CLNN) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.08) by 12...

 hc-wainwright--co-reiterates-buy-on-clene-maintains-7-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $7 price target.

 why-invo-bioscience-shares-are-trading-higher-by-around-73-here-are-20-stocks-moving-premarket

Shares of INVO Bioscience, Inc. (NASDAQ: INVO) rose sharply in today’s pre-market trading after reporting fourth-quarter results.

 clene-highlights-presentation-of-phase-2-visionary-ms-trial-data-at-2024-american-academy-of-neurology-annual-meeting-says-long-term-cnm-au8-treatment-encompassing-up-to-three-years-was-well-tolerated-no-significant-safety-findings-were-observed

Long term extension of the Phase 2 VISIONARY-MS clinical trial of CNM-Au8 demonstrated significant evidence of repair and remye...

 benchmark-reiterates-buy-on-clene-maintains-5-price-target

Benchmark analyst Bruce Jackson reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $5 price target.

 clene-announces-peer-reviewed-publication-characterizing-protein-corona-of-investigational-neurodegenerative-disease-drug-cnm-au8

Proprietary catalytic gold nanocrystals comprising Clene's investigational drug CNM-Au8® develop a protein corona upon expo...

 hc-wainwright--co-reiterates-buy-on-clene-maintains-7-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $7 price target.

 clene-q4-earnings-insights
Clene: Q4 Earnings Insights
03/13/2024 13:40:06

 clene-fy-gaap-eps-047-misses-046-estimate-sales-65400k-beat-55700k-estimate

Clene (NASDAQ:CLNN) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.46) by 2....

 hc-wainwright--co-maintains-buy-on-clene-maintains-7-price-target

HC Wainwright & Co. analyst Joseph Pantginis maintains Clene (NASDAQ:CLNN) with a Buy and maintains $7 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION